Mobile health services provider DocGo goes public via SPAC
DocGo President Anthony Capone explains that the company brings healthcare ‘where it’s needed, when it’s needed,’ and that includes homes, cruises and even correctional facilities.
Shares of Biogen slipped nearly 4% in pre-market trading Wednesday after the biotech company's new Alzheimer's drug, aducanumab, which will be marketed as Aduhel, received a "negative trend vote" from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP).
Ticker
Security
Last
Change
Change %
BIIB
BIOGEN, INC.
260.81
-0.73
-0.28%
The advisory committee's vote, which declines to grant authorization of the treatment in Europe, comes after it was given the green light by the Food and Drug Administration (FDA) in June despite mixed reviews following earlier clinical trials.
BIOGEN INVESTIGATES DEATH OF PATIENT WHO TOOK ALZHEIMER'S DRUG
The medication, which marked the first Alzheimer’s drug to enter the market in nearly 20 years, was granted accelerated approval by the FDA despite an expert panel arguing data to consider the drug’s benefit was insufficient. Following the FDA’s decision to approve it, several panel members resigned.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok